Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFS Provident Financial Services Inc

盘前交易 02-10 04:58:15 EST

23.65

-0.14

-0.59%

最高23.98	最低23.27	成交量54.16万
今开23.73	昨收23.79	日振幅2.98%
总市值30.89亿	流通市值29.83亿	总股本1.31亿
成交额1,286万	换手率0.43%	流通股本1.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident Financial Services Inc","latestPrice":23.65,"timestamp":1770670800000,"preClose":23.79,"halted":0,"volume":541596,"delay":0,"changeRate":-0.005884825556956729,"floatShares":126131374,"shares":130622384,"eps":2.229999,"marketStatus":"盘前交易","change":-0.14,"latestTime":"02-10 04:58:15 EST","open":23.73,"high":23.9789,"low":23.27,"amount":12864505.957776,"amplitude":0.029798,"askPrice":25.84,"askSize":100,"bidPrice":23.42,"bidSize":106,"shortable":3,"etf":0,"ttmEps":2.229999,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770733800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":23.65,"dividendRate":0.040592,"postHourTrading":{"tag":"盘后","latestPrice":23.65,"preClose":23.65,"latestTime":"18:04 EST","volume":44364,"amount":1049209.63,"timestamp":1770678242424,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4609821204255672,"impliedVol":0.2969,"impliedVolPercentile":0.652},"requestUrl":"/m/hq/s/PFS/tweets","defaultTab":"tweets","newsList":[{"id":"2607061264","title":"国产双抗“出海”：FDA已受理依沃西首个海外适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2607061264","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607061264?lang=zh_cn&edition=full","pubTime":"2026-01-30 10:47","pubTimestamp":1769741258,"startTime":"0","endTime":"0","summary":"1月30日，康方生物在官方公众号上宣布，美国食品药品监督管理局（FDA）已受理PD-1/VEGF双抗依沃西联合化疗治疗第三代EGFR-TKI治疗进展的EGFR突变的非鳞状非小细胞肺癌（NSCLC）的生物制品许可申请（BLA）。FDA给出的PDUFA（处方药用户付费法案）日期为2026年11月14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303636681397.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303636681397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PFS","OS","BK4097","BK4211","BK4195"],"gpt_icon":0},{"id":"1166238844","title":"异动解读 | 财报利好，Provident Financial Services盘后大涨9.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166238844","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166238844?lang=zh_cn&edition=full","pubTime":"2026-01-28 06:43","pubTimestamp":1769553802,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc (PFS) 今日盘后股价大幅上涨9.60%，引发了市场广泛关注。消息面上，公司于盘后时段正式发布了其第四季度及整个财年的财务业绩报告，并确定了年度股东大会的日期。财报的发布是影响股价的关键事件，此次盘后大涨通常表明其公布的业绩数据可能超出了市场预期，为投资者带来了积极信号。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PFS"],"gpt_icon":0},{"id":"1133317496","title":"Provident Financial Services, Inc. 公布第四季度及全年业绩并确定年度股东大会日期","url":"https://stock-news.laohu8.com/highlight/detail?id=1133317496","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133317496?lang=zh_cn&edition=full","pubTime":"2026-01-28 06:16","pubTimestamp":1769552177,"startTime":"0","endTime":"0","summary":"Provident Financial Services, Inc. 已正式发布其第四季度财务报告以及整个财年的最终收益数据。与此同时，公司也确定了即将召开的年度股东大会的具体日期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","PFS","BK4211"],"gpt_icon":0},{"id":"2605989254","title":"德曲妥珠单抗胃癌新适应证获批，填补临床治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2605989254","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605989254?lang=zh_cn&edition=full","pubTime":"2026-01-22 19:18","pubTimestamp":1769080687,"startTime":"0","endTime":"0","summary":"由阿斯利康和第一三共共同开发与商业化的优赫得（英文商品名：Enhertu，通用名：注射用德曲妥珠单抗）今天获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627553572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","BK4195","ORR","BK4080","BK4097","PFS","BK4211","ADC","OS"],"gpt_icon":0},{"id":"2605495703","title":"优赫得®在华获批治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495703","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605495703?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:38","pubTimestamp":1769078280,"startTime":"0","endTime":"0","summary":"研究显示，对于局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者，与雷莫西尤单抗+紫杉醇相比，德曲妥珠单抗带来具有显著统计学差异和临床意义的总生存期改善。自一年多前首次在中国获批用于HER2阳性局部晚期或转移性胃癌以来，德曲妥珠单抗仅可用于三线及后线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4868984_ZH68984_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4588","LU1046421795.USD","BK4560","LU2237443895.HKD","BK4231","LU1196500208.SGD","LU2417539215.USD","ORR","ADC","BK4585","BK4097","LU1880398554.USD","OS","LU0109394709.USD","LU1929549753.HKD","IE00BKVL7J92.USD","BK4195","CSCO","LU0320765992.SGD","LU1066051498.USD","LU2506951875.HKD","SG9999001440.SGD","BK4612","LU2237443549.SGD","SG9999015945.SGD","BK4527","LU1221951046.USD","LU1221951129.SGD","LU0792757196.USD","LU1066053197.SGD","LU2247934214.USD","BK4080","LU2237443382.USD","LU1244550494.USD","PFS","LU2462157665.USD","IE00BFMHRM44.USD","LU1894683348.USD","LU0234572021.USD","LU2506952097.USD","AZN","LU0868494617.USD","IE000M9KFDE8.USD","LU1880398471.USD","LU1244550577.SGD","BK4579","LU2237443622.USD","LU2506951958.HKD","SG9999015978.USD","LU1571399168.USD"],"gpt_icon":0},{"id":"1106932996","title":"财报前瞻 ｜Provident Financial Services Inc本季度营收预计小幅增长，机构观点偏中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1106932996","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106932996?lang=zh_cn&edition=full","pubTime":"2026-01-20 10:54","pubTimestamp":1768877699,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc将于2026年01月27日发布最新季度财报，市场关注核心盈利修复与资产质量趋势对估值的影响。市场一致预期显示，Provident Financial Services Inc本季度营收预计为2.08亿美元，同比增长12.34%；调整后每股收益预计为0.56美元，同比增长10.76%；EBIT预计为1.11亿美元，同比增长10.79%。上季度Provident Financial Services Inc实现营收1.94亿美元，毛利率数据未披露；归属母公司净利润为7,172.00万美元，净利率为33.40%；调整后每股收益0.55美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 ｜Provident Financial Services Inc本季度营收预计小幅增长，机构观点偏中性","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS"],"gpt_icon":0},{"id":"1102063075","title":"普罗维登特银行年度经济展望调查：企业主从2025年被动乐观转向2026年主动投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1102063075","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102063075?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:08","pubTimestamp":1767704939,"startTime":"0","endTime":"0","summary":"根据普罗维登特银行发布的年度经济展望调查，美国企业主对未来的心态预计将发生显著转变。调查结果显示，2025年企业界普遍持谨慎乐观态度，更多表现为观望和被动期待；而进入2026年，这种情绪将逐步转化为实际行动，企业主计划扩大资本支出、加大技术创新投入，并积极拓展新市场。普罗维登特银行首席经济学家分析称，这种从\"被动乐观\"到\"主动投资\"的演变，可能成为推动2026年经济加速的关键催化剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4195","BK4211"],"gpt_icon":0},{"id":"2591359889","title":"美国FDA批准Enhertu联合疗法用于一线HER2阳性乳腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2591359889","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591359889?lang=zh_cn&edition=full","pubTime":"2025-12-16 23:45","pubTimestamp":1765899900,"startTime":"0","endTime":"0","summary":"FDA批准阿斯利康（AZN）与第一三共（Daiichi Sankyo，TYO：4568）的fam-trastuzumab deruxtecan（Enhertu）联合帕妥珠单抗（pertuzumab）用于一线治疗，因DESTINY-Breast09试验显示其中位无进展生存期（PFS）达40.7个月，优于标准THP方案的26.9个月；帕妥珠单抗由罗氏（SWX：ROG）销售。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-16/doc-inhaziff7927164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","LU2462157665.USD","PFS","LU1829250122.USD","LU0320765992.SGD","LU2456880835.USD","LU0109394709.USD","LU2236285917.USD","BK4195","BK4211","AZN","BK4568","LU2417539215.USD","BK4585","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"2590451393","title":"吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451393","media":"Minhua笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590451393?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:58","pubTimestamp":1765166299,"startTime":"0","endTime":"0","summary":"在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。III期iMMagine-3试验正在招募中，该研究将Anito-cel与标准治疗比较，预计2026年获得数据；该药物获FDA快速通道、孤儿药和RMAT资格。ICANS 发生率为 8%，其中 1 例为 3 级；其余均为 2 级或更低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4195","SG9999015978.USD","BK4578","IE00B19Z3B42.SGD","ASH","BK4588","GILD","IE00B19Z3581.USD","BK4139","BK4550","KOL","LU0889565916.HKD","SG9999015945.SGD","SG9999015952.SGD","BK4097","LU1674673428.USD","LU0320765992.SGD","LU0289739699.SGD","PFS","LU1571399168.USD","IE0002270589.USD","LU1674673691.USD","ORR","IE00BKVL7J92.USD","BK4568","LU0109394709.USD","IE00B19Z4B17.USD","LU1778281490.HKD","LU1066051498.USD","BK4187","LU1430594728.SGD","OS","LU1585245621.USD","LU0882574055.USD","BK4109","IE00B3T34201.USD","BK4532","IE00B7SZL793.SGD","LU0823416689.USD","LU1839511570.USD","CRS","LU0234570918.USD","IE00B66KJ199.SGD","BK4585","CR","SG9999015986.USD","BK4566","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"2580280025","title":"医药界“泡泡玛特”：递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2580280025","media":"药事纵横","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580280025?lang=zh_cn&edition=full","pubTime":"2025-11-02 08:02","pubTimestamp":1762041764,"startTime":"0","endTime":"0","summary":"VIS-101已在美国和中国完成了初步的安全性和剂量递增研究，目前正在中国完成一项随机剂量范围的II期研究。VIS-101预计将于2026年具备开展III期试验的条件。此次收购已通过新成立的子公司Visara完成的。“我们要做医药行业的‘泡泡玛特’。”傅唯用一个生动的比喻解释，泡泡玛特的核心是“连接设计师与全球渠道”，新桥要做的是“连接中国创新药研发者与全球市场”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251102080748a481f874&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251102080748a481f874&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4195","PFS","BK4211","BK4139","NBP"],"gpt_icon":0},{"id":"2577210243","title":"大行评级丨美银：上调科伦博泰生物目标价至522港元 重申“中性”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2577210243","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577210243?lang=zh_cn&edition=full","pubTime":"2025-10-23 13:37","pubTimestamp":1761197821,"startTime":"0","endTime":"0","summary":"美银证券发表报告，将科伦博泰生物的目标价由471.5港元上调至522港元，重申“中性”评级。临床进展符合预期，但短期授权机会有限。该行指，为反映sac-TMT与A166在无进展生存期方面取得显著改善的鼓舞性数据，以及近期国家药监局批准sac-TMT用于二线EGFR突变非小细胞肺癌及A166用于二线以上HER2阳性乳腺癌，因此上调目标价，并将2025至2027年营收预测上调1%至5%，并调高长期预测。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251023/31730314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BC","BK4190","BK4195","PFS","BK4211"],"gpt_icon":0},{"id":"2577681314","title":"【券商聚焦】交银国际维持康方生物(09926)买入评级 指依沃西较PD-1显著提升一线肺鳞癌PFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2577681314","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577681314?lang=zh_cn&edition=full","pubTime":"2025-10-21 09:06","pubTimestamp":1761008790,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，康方生物 在ESMO大会上公布了HARMONi-6研究的首次PFS分析结果。关键亚组分析显示，依沃西在PD-L1低表达人群中显示长拖尾效应。非头对头比较显示，依沃西中位PFS数值明显好于其他PD-1单靶药物，且相较PD-1的PFS改善绝对值已超过PD-1相较传统化疗的改善程度。依沃西新适应症上市申请已于2025年7月获CDE受理。该机构认为，依沃西最新临床数据已再次验证其相对现有PD-1标准治疗的显著疗效优势，彰显其成长为下一代 I/O 基石产品的潜力。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1968146","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","PD","09926"],"gpt_icon":0},{"id":"1141680300","title":"Provident Bank加强零售业务领导团队，任命Renee Altomonte为执行副总裁兼零售银行总监","url":"https://stock-news.laohu8.com/highlight/detail?id=1141680300","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141680300?lang=zh_cn&edition=full","pubTime":"2025-10-14 20:04","pubTimestamp":1760443464,"startTime":"0","endTime":"0","summary":"Provident Bank加强零售业务领导团队，任命Renee Altomonte为执行副总裁兼零售银行总监","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","PFS","BK4211"],"gpt_icon":0},{"id":"2574112380","title":"韩国生物制药公司Celltrion眼科治疗生物仿制药在美国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2574112380","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574112380?lang=zh_cn&edition=full","pubTime":"2025-10-10 09:51","pubTimestamp":1760061103,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4195","PFS","BK4211"],"gpt_icon":0},{"id":"2574154301","title":"德达博妥单抗三阴乳腺癌一线治疗新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2574154301","media":"医药地理","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574154301?lang=zh_cn&edition=full","pubTime":"2025-10-09 17:03","pubTimestamp":1760000637,"startTime":"0","endTime":"0","summary":"德达博妥单抗是一款靶向TROP2的DXd抗体偶联药物，由第一三共研发，并由阿斯利康与第一三共共同开发与商业化。目前，德达博妥单抗已在全球35个以上国家和地区获批，用于治疗经既往内分泌治疗及化疗后、不可切除或转移性HR阳性、HER2阴性乳腺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009171758a6b1b702&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009171758a6b1b702&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4195","LU1829250122.USD","BK4588","AZN","OS","PFS","LU0109394709.USD","LU2456880835.USD","LU2462157665.USD","BK4568","BK4211","LU2417539215.USD","LU0320765992.SGD","LU0889565916.HKD","LU2236285917.USD","BK4097","BK4007","BK4585"],"gpt_icon":0},{"id":"2573939896","title":"第一三共公布TROPION-Breast02 Ⅲ期研究积极的主要结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2573939896","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573939896?lang=zh_cn&edition=full","pubTime":"2025-10-07 12:19","pubTimestamp":1759810770,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4080","BK4231","BK4097","BK4211","BK4195","OS","ADC","PFS"],"gpt_icon":0},{"id":"2565526301","title":"9月7日康方生物依沃西单抗（AK112）首个全球多中心Ⅲ期临床研究HARMONi的更新数据在世界肺癌大会上公布。该研究评","url":"https://stock-news.laohu8.com/highlight/detail?id=2565526301","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565526301?lang=zh_cn&edition=full","pubTime":"2025-09-07 22:03","pubTimestamp":1757253791,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0965509101.SGD","LU0208291251.USD","LU1116320901.HKD","LU0320765646.SGD","LU1093756325.SGD","LU2324357040.USD","LU1983299246.USD","LU0006306889.USD","LU1093756168.USD","LU1162221912.USD","LU1720050803.USD","LU0265550946.USD","IE0009355771.USD","LU0234572021.USD","LU0211331839.USD","SG9999001440.SGD","MRK","LU0417516738.SGD","LU0348783233.USD","LU0238689110.USD","LU0417516902.SGD","SG9999015358.SGD","LU0348825331.USD","LU0266013472.USD","LU1169590202.USD","SG9999002232.USD","LU0634319403.HKD","LU1291159041.SGD","SG9999014575.USD","LU0289739699.SGD","SG9999014542.SGD","LU1069347547.HKD","IE0002141913.USD","SG9999013999.USD","LU0098860793.USD","PFS","LU1430594728.SGD","LU1023059063.AUD","LU0540923850.HKD","LU1934455277.USD","LU0348767384.USD","PD","LU2461242641.AUD","LU1794554557.SGD","SG9999001176.SGD","09926","IE00BBT3K403.USD","LU0265550359.USD","SGXZ57979304.SGD","SG9999014559.SGD"],"gpt_icon":0},{"id":"2562709883","title":"康方生物Key data readouts for AK112 to validate","url":"https://stock-news.laohu8.com/highlight/detail?id=2562709883","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562709883?lang=zh_cn&edition=full","pubTime":"2025-08-28 11:21","pubTimestamp":1756351315,"startTime":"0","endTime":"0","summary":"AK104和AK112两款药物分别因纳入国家医保目录，在二线及以上的宫颈癌和EGFR突变非小细胞肺癌治疗中推动了销售增长。预计到2026年，随着更多适应症进入NRDL，如一线胃癌、一线宫颈癌和PD-L1阳性非小细胞肺癌等，将进一步加速产品销售。同时，公司计划启动一项针对IO耐药二线肝细胞癌的全球II期注册试验，并探索AK104与AK112联合用药的可能性。此外，Akeso还正在开发HER3ADC和Trop2/Nectin4ADC等早期项目，进一步丰富其研发管线。与此同时，AK104的国际合作潜力也被看好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828114047a4a40388&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828114047a4a40388&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4195","BK4097","BK4211","OS","PFS"],"gpt_icon":1},{"id":"2561695744","title":"国产首个！石药集团HER2双抗拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2561695744","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561695744?lang=zh_cn&edition=full","pubTime":"2025-08-20 19:24","pubTimestamp":1755689095,"startTime":"0","endTime":"0","summary":"8月20日，CDE网站显示，石药集团的HER2双抗安尼妥单抗拟纳入优先审评，用于联合化疗治疗至少接受过一种系统性治疗失败的HER2阳性局部晚期、复发或转移性胃/胃-食管结合部腺癌。安尼妥单抗最初由康宁杰瑞开发，它可以同时结合HER2的两个非重叠表位，导致HER2信号阻断，其治疗效果优于曲妥珠单抗和帕妥珠单抗联用的效果。2021年8月，石药集团获得了安尼妥单抗在中国的独家开发和商业化权益。详细数据尚未公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250820222625a4943914&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250820222625a4943914&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4195","BK4211","PFS"],"gpt_icon":0},{"id":"2559092350","title":"中国罕王2025年上半年收入14.05亿元 同比增长10.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559092350","media":"和讯网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559092350?lang=zh_cn&edition=full","pubTime":"2025-08-15 23:36","pubTimestamp":1755272186,"startTime":"0","endTime":"0","summary":"由此，公司2025年上半年收入为人民币14.05亿元，同比增长10.77%；期内溢利为人民币1.05亿元，同比下降1.99%。面对国内高纯铁行业竞争激烈、价格整体下行的市场环境，公司高纯铁业务按照既定的战略目标，从采购、生产、销售等全流程提升管理水平，稳步推进各项具体工作，2025年上半年实现了扭亏为盈，录得税前利润人民币14,956千元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250815233939a48b1efb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250815233939a48b1efb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4195","BK4211","PFS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.provident.bank","stockEarnings":[{"period":"1week","weight":0.0419},{"period":"1month","weight":0.1772},{"period":"3month","weight":0.254},{"period":"6month","weight":0.2248},{"period":"1year","weight":0.2318},{"period":"ytd","weight":0.1975}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Provident Financial Services, Inc.是一家特拉华州公司，于2003年1月15日成为Provident Bank的控股公司。该公司通过其子公司银行开展业务，该银行是一家面向社区和客户的银行，目前在新泽西州北部和中部以及宾夕法尼亚州的雄鹿县、利哈伊县和北安普敦县以及纽约州的拿骚县和皇后区经营全方位服务的分行和贷款生产办事处。该银行还通过其全资子公司Beacon Trust Company提供信托和财富管理服务，并通过其全资子公司Provident Protection Plus, Inc.提供保险服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.304348,"avgChangeRate":-0.021667},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.011114},{"month":3,"riseRate":0.434783,"avgChangeRate":-0.003684},{"month":4,"riseRate":0.478261,"avgChangeRate":0.005908},{"month":5,"riseRate":0.478261,"avgChangeRate":-0.011563},{"month":6,"riseRate":0.478261,"avgChangeRate":-0.000381},{"month":7,"riseRate":0.652174,"avgChangeRate":0.040433},{"month":8,"riseRate":0.521739,"avgChangeRate":-0.005847},{"month":9,"riseRate":0.347826,"avgChangeRate":-0.017472},{"month":10,"riseRate":0.652174,"avgChangeRate":0.032054},{"month":11,"riseRate":0.695652,"avgChangeRate":0.033616},{"month":12,"riseRate":0.565217,"avgChangeRate":0.013167}],"exchange":"NYSE","name":"Provident Financial Services Inc","nameEN":"Provident"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Provident Financial Services Inc,PFS,Provident Financial Services Inc股票,Provident Financial Services Inc股票老虎,Provident Financial Services Inc股票老虎国际,Provident Financial Services Inc行情,Provident Financial Services Inc股票行情,Provident Financial Services Inc股价,Provident Financial Services Inc股市,Provident Financial Services Inc股票价格,Provident Financial Services Inc股票交易,Provident Financial Services Inc股票购买,Provident Financial Services Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}